Summit Therapeutics
SMMT
21 hedge funds and large institutions have $50.9M invested in Summit Therapeutics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
67% more capital invested
Capital invested by funds: $30.5M → $50.9M (+$20.4M)
50% more funds holding
Funds holding: 14 → 21 (+7)
1.42% more ownership
Funds ownership: 4.35% → 5.77% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPU
Lansdowne Partners (UK)
London,
United Kingdom
|
+$8.64M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.89M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.62M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$1.3M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$106K |
| 2 |
Axa
Paris,
France
|
-$50K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3K |
SMMT Hedge Fund Activity: Q3 2017 in Review
21 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2017, worth a combined $50.9M — up 67% from $30.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SMMT positions and 1 closed out — a net gain of 7 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Lansdowne Partners (UK), adding an estimated $8.64M. The largest seller was Knoll Capital Management, cutting an estimated $106K.
- 21 institutional investors held Summit Therapeutics (SMMT) as of Q3 2017, up from 14 in Q2 2017.
- Funds reported $50.9M of Summit Therapeutics stock for Q3 2017, up 67% quarter-over-quarter.
- 8 funds opened new Summit Therapeutics positions in Q3 2017 and 1 closed out, a net change of +7 holders.
- The largest Summit Therapeutics buyer in Q3 2017 was Lansdowne Partners (UK), an estimated $8.64M added.
- The largest Summit Therapeutics seller in Q3 2017 was Knoll Capital Management, an estimated $106K sold.
Based on aggregated 13F filings for Q3 2017.